Biofourmis

Biofourmis, founded in 2015, is a global leader in virtual care and digital medicine, specializing in AI-driven health analytics platforms that integrate data from clinical-grade wearables to predict and manage health conditions. Their solutions span the continuum of care, from drug development to in-home patient management, aiming to enhance patient outcomes and reduce healthcare costs.

The company has attracted significant investment from a diverse group of investors, including General Atlantic, CVS Health, SoftBank Vision Fund, Intel Capital, Openspace Ventures, EDBI, MassMutual Ventures, and Sequoia Capital. In April 2022, Biofourmis raised $300 million in a Series D funding round led by General Atlantic, elevating its valuation to unicorn status.

What sets Biofourmis apart is its FDA-cleared, AI-powered Biovitals™ analytics engine, which continuously learns and adjusts to provide personalized care recommendations. By analyzing real-time physiological data, the platform enables proactive interventions, addressing challenges such as hospital capacity constraints, staffing shortages, and the need for continuous patient monitoring.

In the artificial intelligence landscape, Biofourmis operates within the category of AI-driven health analytics and remote patient monitoring. Their technology applies machine learning algorithms to physiological data, facilitating predictive analytics and personalized care in both clinical and home settings.

For more information, please visit biofourmis.com.

To claim this startup page, go to the Contact page and send us a message with your full name, startup name, job title, and startup email address. We will review your request and get back to you. Once verified, you can update your startup information.